Non-Industrial Robots Market is Expand at a CAGR of 18.8% During Forecast Period – By Fact.MR

Robotics is gradually changing how routine tasks are carried out; their adoption simplifies work, saves time, and increases overall productivity.

Every industry, including the commercial and domestic sectors, uses robots for all jobs, simple or complex. Due to the growing demand from end-use sectors like healthcare, the military, research and development, and other industries, non-industrial robots are expected to experience rapid growth.

“Demand across Defense Sector to Supplement Non-Industrial Robots Sales”

Robots with the advancing technology, witness high adoption across various end-use verticals over the period. The defense sector creates high growth opportunities for non-industrial robots as they ease out difficult military tasks.

For instance, the use of robots to spy, deliver goods and services, rescue operations, robot dogs for search missions, and others. Such factors augment the sales of non-industrial robots.

Further, the use of sensors, autonomy, navigation/control systems, and energy/propulsion systems, among others, assists military personnel to accomplish the mission efficiently. Owing to such factor military is spending highly on non-industrial robots.

Competitive Analysis

Prominent non-industrial robots Diligent Robotics, ReWalk Robotics, Barrett Advanced Robotics, Stryker, Hanson Robotics, Pal Robotics, UBTECH Robotics, Macco Robotics, Intuitive Robots, Samsung Electronics, and Skydio Robots, among others.

Market titans are experiencing high demand for non-industrial robots due to their adoption across various end-use verticals. Manufacturers are also integrating robots with advanced technology to enhance their performance and cater to the needs of the end-users. In addition, long-term trade relations with end-users enable market players to survive in unfavourable trade situations.

Fact.MR has provided detailed information about the price points of key manufacturers of non-industrial robots positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

 

These insights are based on a report on Non-Industrial Robots Market by Fact.MR. 

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.